Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia.

Bacterial secondary infections COVID-19 Pneumonia SARS-CoV-2 Sepsis

Journal

Journal of intensive care
ISSN: 2052-0492
Titre abrégé: J Intensive Care
Pays: England
ID NLM: 101627304

Informations de publication

Date de publication:
18 Jan 2021
Historique:
received: 19 10 2020
accepted: 06 01 2021
entrez: 19 1 2021
pubmed: 20 1 2021
medline: 20 1 2021
Statut: epublish

Résumé

SARS-CoV-2 may cause acute lung injury, and secondary infections are thus relevant complications in patients with COVID-19 pneumonia. However, detailed information on community- and hospital-acquired infections among patients with COVID-19 pneumonia is scarce. We identified 220 SARS-CoV-2-positive patients hospitalized at the University Hospital Basel, Switzerland (between 25 February and 31 May 2020). We excluded patients who declined the general consent (n = 12), patients without clinical evidence of pneumonia (n = 29), and patients hospitalized for < 24 h (n = 17). We evaluated the frequency of community- and hospital-acquired infections using respiratory and blood culture materials with antigen, culture-based, and molecular diagnostics. For ICU patients, all clinical and microbial findings were re-evaluated interdisciplinary (intensive care, infectious disease, and clinical microbiology), and agreement reached to classify patients with infections. In the final cohort of 162 hospitalized patients (median age 64.4 years (IQR, 50.4-74.2); 61.1% male), 41 (25.3%) patients were admitted to the intensive care unit, 34/41 (82.9%) required mechanical ventilation, and 17 (10.5%) of all hospitalized patients died. In total, 31 infections were diagnosed including five viral co-infections, 24 bacterial infections, and three fungal infections (ventilator-associated pneumonia, n = 5; tracheobronchitis, n = 13; pneumonia, n = 1; and bloodstream infection, n = 6). Median time to respiratory tract infection was 12.5 days (IQR, 8-18) and time to bloodstream infection 14 days (IQR, 6-30). Hospital-acquired bacterial and fungal infections were more frequent among ICU patients than other patients (36.6% vs. 1.7%). Antibiotic or antifungal treatment was administered in 71 (43.8%) patients. Community-acquired viral and bacterial infections were rare among COVID-19 pneumonia patients. By contrast, hospital-acquired bacterial or fungal infections were frequently complicating the course among ICU patients.

Identifiants

pubmed: 33461613
doi: 10.1186/s40560-021-00526-y
pii: 10.1186/s40560-021-00526-y
pmc: PMC7812551
doi:

Types de publication

Journal Article

Langues

eng

Pagination

10

Références

Cleve Clin J Med. 2020 Nov 2;87(11):659-663
pubmed: 32393593
Infect Dis (Lond). 2020 Nov - Dec;52(12):919-922
pubmed: 32779951
Lancet Respir Med. 2020 Jun;8(6):e48-e49
pubmed: 32445626
Ann Intensive Care. 2020 Sep 7;10(1):119
pubmed: 32894364
J Crit Care. 2019 Apr;50:59-65
pubmed: 30481669
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Chest. 2011 Mar;139(3):555-562
pubmed: 20930007
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Crit Care Med. 2013 Nov;41(11):2467-75
pubmed: 24162674
Crit Care Med. 2012 May;40(5):1487-98
pubmed: 22511131
Clin Infect Dis. 2020 Jun 16;:
pubmed: 32544219
Eur J Clin Invest. 2020 Oct;50(10):e13319
pubmed: 32535894
Ann Intensive Care. 2020 Jun 1;10(1):71
pubmed: 32488446
Clin Microbiol Infect. 2017 Feb;23(2):78-85
pubmed: 27569710
Influenza Other Respir Viruses. 2013 Mar;7(2):168-76
pubmed: 22487223
Intensive Care Med. 2012 Nov;38(11):1761-8
pubmed: 22895826
Clin Infect Dis. 2020 May 01;:
pubmed: 32361747
Intensive Care Med. 2020 May;46(5):888-906
pubmed: 32157357
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
J Med Virol. 2020 Oct;92(10):1759-1760
pubmed: 32275075
Am J Respir Crit Care Med. 2020 Sep 15;202(6):902-903
pubmed: 32687389
J Infect Dis. 2020 Sep 14;222(8):1270-1279
pubmed: 32726441
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
JAMA. 2013 Jan 16;309(3):275-82
pubmed: 23321766
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399
pubmed: 32603803

Auteurs

Kirstine K Søgaard (KK)

Clinical Bacteriology and Mycology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. KirstineKobberoee.Soegaard@usb.ch.
Department of Biomedicine, Applied Microbiology Research, University of Basel, Basel, Switzerland. KirstineKobberoee.Soegaard@usb.ch.

Veronika Baettig (V)

Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.

Michael Osthoff (M)

Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Department of Clinical Research, University Hospital Basel, Basel, Switzerland.

Stephan Marsch (S)

Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.

Karoline Leuzinger (K)

Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.

Michael Schweitzer (M)

Clinical Bacteriology and Mycology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Department of Biomedicine, Applied Microbiology Research, University of Basel, Basel, Switzerland.

Julian Meier (J)

Department of Biomedicine, Applied Microbiology Research, University of Basel, Basel, Switzerland.
Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.

Stefano Bassetti (S)

Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Department of Clinical Research, University Hospital Basel, Basel, Switzerland.

Roland Bingisser (R)

Department of Emergency Medicine, University Hospital Basel, Basel, Switzerland.

Christian H Nickel (CH)

Department of Emergency Medicine, University Hospital Basel, Basel, Switzerland.

Nina Khanna (N)

Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.

Sarah Tschudin-Sutter (S)

Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Department of Clinical Research, University Hospital Basel, Basel, Switzerland.

Maja Weisser (M)

Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.

Manuel Battegay (M)

Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.

Hans H Hirsch (HH)

Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Hans Pargger (H)

Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.

Martin Siegemund (M)

Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.

Adrian Egli (A)

Clinical Bacteriology and Mycology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. Adrian.Egli@usb.ch.
Department of Biomedicine, Applied Microbiology Research, University of Basel, Basel, Switzerland. Adrian.Egli@usb.ch.

Classifications MeSH